Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Nanotechnology and Integrated Bioengineering Centre, Ulster University-Jordanstown Campus, Newtownabbey, UK.
BMJ Open. 2021 Jun 29;11(6):e048142. doi: 10.1136/bmjopen-2020-048142.
To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies.
Nationwide serological study.
Northern Ireland, UK, May 2020-February 2021.
Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset.
SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples.
We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%).
Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting.
评估 SARS-CoV-2 感染后体液免疫应答的动态变化和持久性,并评估英国 RTC AbC-19 快速检测侧向流动免疫分析(LFIA)在 SARS-CoV-2 刺突蛋白 IgG 抗体目标条件下的专业应用性能。
全国血清学研究。
英国北爱尔兰,2020 年 5 月至 2021 年 2 月。
从普通人群(n=279)、北爱尔兰医护人员(n=195)、大流行前的献血和研究(n=223)以及通过恢复期血浆计划(n=183)中采集了血浆样本。对 101 名血浆供体进行了随访,在症状出现后 11 个月内进行了连续采样。
使用罗氏 Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM、雅培 SARS-CoV-2 IgG 和 EuroImmun IgG SARS-CoV-2 ELISA 免疫分析试剂盒,随时间检测血浆样本中的 SARS-CoV-2 抗体水平。使用三参考标准系统评估英国 RTC AbC-19 LFIA 的灵敏度和特异性,以建立一个由 330 个阳性和 488 个阴性 SARS-CoV-2 IgG 样本组成的特征性面板。
我们在感染后长达 10 个月的时间内检测到 SARS-CoV-2 IgG 抗体的持续存在,这至少通过两种实验室免疫分析方法得到证实。在已知的阳性队列中,英国 RTC AbC-19 LFIA 的灵敏度为 97.58%(95.28%至 98.95%),在已知的阴性队列中,特异性为 99.59%(98.53%至 99.95%)。
通过对大流行前和大流行期间个体的综合分析,我们显示出在使用 EuroImmun ELISA 检测时,可检测到 IgG 抗体水平超过 46 周,这为感染后后期的抗体水平提供了深入了解。我们在实验室环境下对 AbC-19 快速检测 SARS-CoV-2 刺突蛋白 IgG 抗体检测的实验室验证性能指标进行了良好的评估。